MCI Onehealth Announces Investment in and Commercial Support for Acorn Biolabs, Inc., Paving New Frontier in Precision Medici...
April 15 2021 - 4:19PM
MCI Onehealth Technologies Inc. ("MCI Onehealth",
“MCI” or the "Company") (TSX: DRDR), a clinician-led healthcare
technology company focused on increasing access to and quality of
healthcare, has announced an investment of $250,000 with
Acorn Biolabs, Inc. (“Acorn Biolabs,” “Acorn”), a
Toronto-based biotechnology company. Acorn Biolabs is
revolutionizing regenerative and precision medicine through its
easy, affordable, and non-invasive stem cell collection, analysis,
and cryopreservation service which is up to 80 per cent more
cost-effective than the current exclusionary industry average.
This investment allows MCI Onehealth to accelerate execution of
its precision health and technology roadmap, while also supporting
the Company’s long-term vision of building a data-driven,
technology-enabled health services platform. As a leader in primary
care, MCI Onehealth’s collaboration with Acorn Biolabs further
expands MCI’s business from a brick-and-mortar clinic network
towards a data-driven, technology-enabled health services
platform.
“MCI Onehealth is unlocking an exciting new phase of precision
medicine that will play an integral role in the future of
healthcare,” said Alexander Dobranowski, MD, CEO of MCI
Onehealth. “By expanding our personalized and preventative
healthcare services through innovations like Acorn’s
industry-leading stem cell harvesting and storage, our ongoing
mission to improve patient outcomes and save lives is made
significantly stronger.”
In addition to the capital investment, MCI will be providing
commercial support to Acorn’s innovative solution for live cell
collection. Select MCI clinics will begin offering Acorn services,
including non-invasive hair follicle-based stem cell collection and
storage, as well as live cell and genetic analytics, with
availability throughout the MCI network by the end of the year.
By freezing a patient’s healthy cells and allowing them to be
leveraged when needed, Acorn Biolabs aims to give its patients the
ability to live longer, healthier lives through regenerative
medicine.
“This is just the beginning of our story with MCI Onehealth as
both a capital investor in our stem cell technology, and by
offering it to an entirely new audience of Canadians,” said
Dr. Drew Taylor, Co-founder and CEO at Acorn
Biolabs. “This is a very exciting opportunity which
integrates our technology into MCI’s large and well operated
network of medical clinics and allows us to have a role in
advancing precision health as a whole.”
This strategic relationship will allow MCI Onehealth to provide
commercial support to Acorn Biolabs by offering its innovative and
industry leading affordable stem cell collection and storage to its
850,000+ yearly patients while also expanding their selection of
service offerings. MCI Onehealth is committed to growth as a means
of empowering physicians and putting patients’ health first.
As a leader in primary care, MCI Onehealth’s partnership with
Acorn Biolabs further expands its business from a brick-and-mortar
clinic network towards a data-driven, modernized technology-enabled
health services platform.
About Acorn Biolabs, Inc.Acorn helps you
prepare for the future of regenerative medicine by banking your
best cells today. Led by Dr. Drew Taylor and borne out of years of
research, Acorn is a healthcare technology company based in Toronto
and backed by investors including Real Ventures, Globalive, Pool
Global Partners and Epic Capital Management. Acorn is focused on
giving every individual the opportunity to live a longer, healthier
life with its patented non-invasive stem cell collection, analysis
and cryopreservation service. For more information, visit
acorn.me
About MCI OnehealthMCI
Onehealth is a healthcare technology company focused on empowering
patients and doctors with advanced technologies to increase access,
improve quality, and reduce healthcare costs. As part of the
healthcare community for over 30 years, MCI Onehealth operates one
of Canada’s leading primary care networks with 25 clinics, serves
over 850,000 patients annually and had over 200,000 telehealth
visits last year. MCI Onehealth additionally offers an expanding
suite of occupational health service offerings that support a
growing list of over 250 corporate customers. Led by a proven
management team of doctors and experienced executives, MCI
Onehealth remains focused on executing a strategy centered around
acquiring technology and health services that complement the
company’s current roadmap.For more information,
visit mcionehealth.com
For IR enquiries please contact:Fernando
Massalin | Ir@mcionehealth.com | +1 (416) 440-4040 ext 155
For media enquiries please contact:Braden
Rosner | braden@yprcanada.com | +1 (647) 982-8549
Forward-Looking Statements
This press release contains forward-looking information and
forward-looking statements (together, “forward-looking statements”)
within the meaning of applicable securities legislation, which
reflect MCI Onehealth’s current expectations regarding future
events, including statements relating to: the relationship between
the Company and Acorn (including the expected benefits thereof),
the impact of the relationship with Acorn on MCI Onehealth’s
service offerings, technology roadmap and long-term strategic plan,
the scope and timing of integrating Acorn’s services into MCI
Onehealth clinics, Acorn’s goals and strategic plan, Acorn’s role
in the regenerative and precision medicine industry and the
possibility of future collaborations between Acorn and MCI
Onehealth. In some cases, but not necessarily in all cases,
forward-looking statements can be identified by the use of words or
phrases such as “allows”, “future”, “revolutionizing”, “up to”,
“towards”, “aims to”, “just the beginning”, “expanding” or
variations of such words and phrases or state that certain actions,
events or results “may”, “could”, “would”, “might” or “will” occur.
Forward-looking statements are based on a number of assumptions and
is subject to a number of risks and uncertainties, many of which
are beyond MCI Onehealth’s control, which could cause actual
results and events to differ materially from those that are
disclosed in or implied by such forward-looking statements. Such
risks and uncertainties include difficulties or delays integrating
Acorn’s services with those of the Company, technologies and
services not functioning as expected, third parties not using
technologies and services as expected, economic conditions making
technologies and services less attractive than anticipated,
competitors in the industry, the possibility of a breakdown in the
relationship between Acorn and the Company, and other factors
discussed under “Risk Factors” in the Company’s annual information
form for the year ended December 31, 2020 which is available under
the Company’s profile on SEDAR at www.sedar.com. All
forward-looking statements made in this press release are made as
of the date hereof and MCI Onehealth does not undertake any
obligation to update such forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable law.
MCI Onehealth Technologies (TSX:DRDR)
Historical Stock Chart
From Sep 2024 to Oct 2024
MCI Onehealth Technologies (TSX:DRDR)
Historical Stock Chart
From Oct 2023 to Oct 2024